Rebecca Landy, PhD, is a principal scientist for the Cancer Risk Factors and Screening Research team within the Surveillance & Health Equity Science (SHES) department of the American Cancer Society (ACS). Her research focuses on cancer screening, prevention and early detection of cancer, across multiple cancer sites. She is interested in the evaluation of emerging screening technology and screening eligibility criteria for targeted cancer screening programs, such as lung cancer.
Before joining ACS, Landy was a research fellow in the Clinical Epidemiology Unit, Division of Cancer Epidemiology and Genetics, National Cancer Institute (NCI). Her research focused on the natural history of cancer, and using this knowledge to inform cancer screening, prevention and early diagnosis.
At Queen Mary University of London her research focused on cervical cancer screening and modelling the impact of HPV vaccination on cervical cancer incidence.
At NCI, her research focused on modelling the impact of HPV vaccination on HPV-associated oropharyngeal cancer and evaluating the population-level impact of lung cancer screening guidelines.
Her research has informed national and international cervical and lung cancer screening guidelines.
She is also interested in new screening technology, including cervical self-sampling and capsule-sponge testing for Barrett's esophagus, a precursor condition to esophageal adenocarcinoma.
For a full list of Dr. Landy’s publications, visit her Google Scholar page.
I live in Philadelphia, PA, though I was born and raised in England. I enjoy hiking and traveling.